Compare INMD & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INMD | VTYX |
|---|---|---|
| Founded | 2008 | 2018 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 879.2M | 990.9M |
| IPO Year | 2019 | 2021 |
| Metric | INMD | VTYX |
|---|---|---|
| Price | $15.04 | $13.98 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 6 | 7 |
| Target Price | ★ $16.75 | $13.50 |
| AVG Volume (30 Days) | 857.9K | ★ 5.9M |
| Earning Date | 02-10-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.42 | N/A |
| EPS | ★ 2.21 | N/A |
| Revenue | ★ $364,494,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.33 | N/A |
| P/E Ratio | $6.98 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.14 | $0.78 |
| 52 Week High | $19.78 | $25.00 |
| Indicator | INMD | VTYX |
|---|---|---|
| Relative Strength Index (RSI) | 57.72 | 75.68 |
| Support Level | $13.89 | $13.94 |
| Resistance Level | $15.90 | $14.07 |
| Average True Range (ATR) | 0.44 | 0.19 |
| MACD | 0.07 | 0.01 |
| Stochastic Oscillator | 61.84 | 28.53 |
InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions in the United States. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF and Morpheus8. The majority of its revenue comes from the United States.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.